Sancuso: transdermal patch formulation of nausea drug

ProStrakan has launched Sancuso (granisetron) transdermal patch for the treatment of chemotherapy-induced nausea and vomiting.

Patients should avoid exposing the patch application site to sunlight or direct heat during and for 10 days after removal.

It is the first 5HT3 antagonist to be made available in this form.

Patients should apply a single Sancuso patch (releasing granisetron 3.1mg/24 hours) to the upper arm or abdomen 24 to 48 hours before chemotherapy. The patch should be removed a minimum of 24 hours after completion of the chemotherapy but can be worn continuously for up to 7 days.

Non-inferior to oral granisetron

In clinical trials, Sancuso was non-inferior to oral granisetron (2mg once daily) and was generally well tolerated. Constipation was the most commonly reported adverse effect. Mild application site reactions were reported, which did not lead to discontinuation of treatment. If a severe or generalised skin reaction occurs, the patch should be removed.

View Sancuso drug record

Further information: ProStrakan

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...